Penumbra, Inc. to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum
Penumbra, Inc. (NYSE: PEN) announced its participation in the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020, at 1:30 PM ET (10:30 AM PT).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Penumbra, Inc. (NYSE: PEN) announced its participation in the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020, at 1:30 PM ET (10:30 AM PT). The event will showcase the company's innovative healthcare solutions. Interested parties can access a webcast of the presentation through the company's website, available for two weeks post-event. Penumbra specializes in designing and market-leading products for challenging medical conditions, primarily serving U.S., Europe, Canada, and Australia.
Details
News Market Reaction – PEN
The recorded move for PEN in the trading session of this news was -3.49%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALAMEDA, Calif., Nov. 6, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020.
Event: Canaccord Genuity Virtual MedTech & Diagnostics Forum
Date: Thursday, November 19, 2020
Time: 1:30pm ET / 10:30am PT
A webcast of the presentation will be available by visiting the investors' section of the company's website at www.penumbrainc.com. The webcast will be available on the company's website for at least two weeks following the event.
About Penumbra
Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra sells its products to hospitals and healthcare providers primarily through its direct sales organization in the United States, most of Europe, Canada and Australia, and through distributors in select international markets. The Penumbra logo is a trademark of Penumbra, Inc. For more information, visit www.penumbrainc.com.
Investor Relations
Penumbra, Inc.
510-995-2461
investors@penumbrainc.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/penumbra-inc-to-present-at-the-canaccord-genuity-virtual-medtech--diagnostics-forum-301167651.html
SOURCE Penumbra, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.